La et al. (2022) found that the reduction of UA by SGLT-2 inhibitors was related to its inhibition of low-grade inflammation. In addition, animal experiments showed that empagliflozin attenuates hyperuricemia by upregulation of ABCG2 via the AMPK/AKT/CREB signaling pathway in type 2 diabetic mice (Lu et al., 2020). Butt et al. (2023) suggested that the lowering effect of SGLT-2 inhibitors on UA can reduce the required dosage of urate-lowering therapy drugs. The gene discussed is CREB1; the disease is hyperuricemia.